Cargando…

The brain strikes back: Hypothalamic targets for peripheral CB(1) receptor inverse agonism

Detalles Bibliográficos
Autor principal:	Cota, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5641597/ https://www.ncbi.nlm.nih.gov/pubmed/29031708 http://dx.doi.org/10.1016/j.molmet.2017.07.003

Ejemplares similares

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

mTORC1 and CB1 receptor signaling regulate excitatory glutamatergic inputs onto the hypothalamic paraventricular nucleus in response to energy availability
por: Mazier, Wilfrid, et al.
Publicado: (2019)

Structural basis for receptor selectivity and inverse agonism in S1P(5) receptors
por: Lyapina, Elizaveta, et al.
Publicado: (2022)

Beta-2 Agonism: A Potential Therapeutic Target for Dyslipidemia
por: Davidson, Michael H.
Publicado: (2015)

Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats
por: Delis, Foteini, et al.
Publicado: (2016)

CB1 Agonism Alters Addiction-Related Behaviors in Mice Lacking Mu or Delta Opioid Receptors
por: Roeckel, Laurie-Anne, et al.
Publicado: (2018)

Inverse agonism and its therapeutic significance
por: Khilnani, Gurudas, et al.
Publicado: (2011)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Prostaglandin I(2) Receptor Agonism for Proteinuria and Diabetes: Good for the Goose and Good for the Gander?
por: Menon, Madhav C., et al.
Publicado: (2016)

Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity
por: Franks, Lirit N., et al.
Publicado: (2016)

Serendipity strikes again
por: Grünbaum, F. Alberto
Publicado: (2022)

Side Chain Orientation of Tryptophan Analogues Determines Agonism and Inverse Agonism in Short Ghrelin Peptides
por: Nicke, Lennart, et al.
Publicado: (2019)

Target RNAs Strike Back on MicroRNAs
por: Fuchs Wightman, Federico, et al.
Publicado: (2018)

The Keloid Strikes Back
por: Wang, Howard D., et al.
Publicado: (2012)

The Measles Strikes Back
por: Kang, Jin Han, et al.
Publicado: (2019)

The Empire Strikes Back?
por: Lim, Cheong, et al.
Publicado: (2023)

Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor
por: Chakraborty, Raja, et al.
Publicado: (2014)

Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity
por: Berg, Kelly A, et al.
Publicado: (2018)

A Systematic Review of Inverse Agonism at Adrenoceptor Subtypes
por: Michel, Martin C., et al.
Publicado: (2020)

D2/D3 Receptor Agonism: Paving the Way for a New Therapeutic Target for Taste Disorders in Parkinson’s Disease and Other Conditions?
por: Mantovani, Elisa, et al.
Publicado: (2022)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Uncovering Caffeine’s Adenosine A(2A) Receptor Inverse Agonism in Experimental Parkinsonism
por: Fernández-Dueñas, Víctor, et al.
Publicado: (2014)

Inverse agonism of retinoic acid receptors directs epiblast cells into the paraxial mesoderm lineage
por: Russell, Ryan P., et al.
Publicado: (2018)

SIRT3: Striking at the heart of aging
por: Liu, Yufei, et al.
Publicado: (2011)

Bilirubin: Striking Gold in Diabetic Vasculopathy?
por: Durante, William
Publicado: (2015)

Policy lessons from physicians’ strikes
por: Marchildon, Gregory P
Publicado: (2013)

A strike against indolent neuroblastoma
por: Cook, April, et al.
Publicado: (2020)

Does FFAR4 Agonism have Therapeutic Potential in Cardiometabolic Disease?
por: Lay, Abigail C
Publicado: (2021)

Striking errors in the methodology, execution, and conclusions of the Cochrane Library review of spinal cord stimulation for low back pain by Traeger et al.
por: Durbhakula, Shravani, et al.
Publicado: (2023)

Computational Prediction and Biochemical Analyses of New Inverse Agonists for the CB1 Receptor
por: Scott, Caitlin E., et al.
Publicado: (2015)

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice
por: van Eenige, Robin, et al.
Publicado: (2021)

Complexes of the neurotensin receptor 1 with small-molecule ligands reveal structural determinants of full, partial, and inverse agonism
por: Deluigi, Mattia, et al.
Publicado: (2021)

Expression of Functional Cannabinoid Type-1 (CB(1)) Receptor in Mitochondria of White Adipocytes
por: Pagano Zottola, Antonio C., et al.
Publicado: (2022)

Heavy neutrinos: the heterodox strikes back
por: Salati, Pierre
Publicado: (1991)

Commentary: Combination surgery for ischemic cardiomyopathy: The preemptive strike
por: Glower, Donald D.
Publicado: (2021)

Agonism and Antagonism at the Insulin Receptor
por: Knudsen, Louise, et al.
Publicado: (2012)

Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB(1) Receptors: A Step Back into the Future
por: Panagis, George, et al.
Publicado: (2014)

Therapeutic potential of a novel peripherally restricted CB1R inverse agonist on the progression of diabetic nephropathy
por: Jacquot, Laetitia, et al.
Publicado: (2023)

Atherosclerosis in chronic kidney disease: Striking while the Iron is labile
por: Modi, G. K., et al.
Publicado: (2013)

Cannabigerol Action at Cannabinoid CB(1) and CB(2) Receptors and at CB(1)–CB(2) Heteroreceptor Complexes
por: Navarro, Gemma, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_drhruo42kennoluujuuc1cpp8l